Search - tctmd.com

Displaying 701 - 720 of 1578

Sort: Relevancy | Date

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

August 26, 2017

STEMI: Treatment Strategies, Drugs And Devices

Presentation iASSESS 2017

STEMI: Treatment Strategies, Drugs And Devices

Presenter: Dharam J. Kumbhani

August 24, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Comparative Efficacy and Safety of Reperfusion Therapy With Fibrinolytic Agents in STEMI Patients

Presentation

Comparative Efficacy and Safety of Reperfusion Therapy With Fibrinolytic Agents in STEMI Patients

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

News Daily News

Costs Up, Usage Down: Hospitals Curtailed Use of CV Meds When Prices Soared

August 15, 2017

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

Presentation

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

August 14, 2017

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Genetic Study Supports Link Between Serum Calcium and CAD Risk

News Daily News

Genetic Study Supports Link Between Serum Calcium and CAD Risk

July 26, 2017

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Higher In-Hospital Mortality After STEMI Linked to Lack of Health Insurance

News Daily News

Higher In-Hospital Mortality After STEMI Linked to Lack of Health Insurance

July 20, 2017

Predictors of Long-term Major CV Events and Death in Patients With Unprotected Left Main CAD

Presentation

Predictors of Long-term Major CV Events and Death in Patients With Unprotected Left Main CAD

July 20, 2017

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

News Daily News

Predictors of Bad Outcomes After Unprotected Left Main Disease Similar Regardless of Treatment

July 20, 2017

No Racial Disparity in Post-PCI Mortality Seen at the VA

News Daily News

No Racial Disparity in Post-PCI Mortality Seen at the VA

July 19, 2017

Black Men Have Twofold Higher Risk of Dying From First CHD Event

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.